NCR Online Journal

80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment

 Breaking News
  • No posts were found

80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment

March 23
20:49 2023
80+ Active Companies working to Develop 100+ Pipeline Therapies for Type 1 Diabetes Treatment

DelveInsight’s, “Type 1 Diabetes Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including Type 1 Diabetes clinical trials and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Type 1 Diabetes Pipeline Report

 

  • DelveInsight’s Type 1 Diabetes Pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.

 

  • The leading Type 1 Diabetes Companies such as Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others are evaluating new type 1 diabetes drugs to improve the treatment landscape.

 

  • The promising Type 1 Diabetes Therapies in various stages of development such as LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.

 

  • The Type 1 Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence R&D Type 1 Diabetes. The Type 1 Diabetes pipeline therapies under development are focused on novel approaches to treat/improve Type 1 Diabetes.

 

Explore more about the latest breakthroughs in the Type 1 Diabetes Treatment Landscape @ Type 1 Diabetes Pipeline Outlook

 

Type 1 Diabetes Overview

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth.

 

Recent Developmental Activities in Type 1 Diabetes Treatment Landscape

 

• In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.

 

• In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.

 

• In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.

 

• In May 2022, Sernova and Evotec are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec’s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15M and will make a further investment of €5M.

 

• In March 2022, Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.

 

• In January 2022, Remedium Bio announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.

 

Type 1 Diabetes Emerging Drugs

 

• Teplizumab: Prevention Bio

 

• Emricasan: Histogen

 

• VX-880: Vertex Pharmaceuticals

 

Discover more about therapy set to grab substantial Type 1 Diabetes Pipeline Landscape @ Type 1 Diabetes Ongoing Clinical Trial Analysis

 

Type 1 Diabetes Pipeline Therapeutics Analysis

There are approx. 80+ key companies which are developing therapies for Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio.

 

DelveInsight’s Type 1 Diabetes Pipeline Report covers around 100+ products under different phases of clinical development-

 

• Late-stage products (Phase III)

 

• Mid-stage products (Phase II)

 

• Early-stage product (Phase I) along with the details of

 

• Pre-clinical and Discovery stage candidates

 

• Discontinued & Inactive candidates

 

Know which Type 1 Diabetes Treatment Drugs are expected to score the touchdown first @ Type 1 Diabetes Treatment Landscape

 

Scope of the Type 1 Diabetes Pipeline Report

 

  • Coverage- Global

 

  • Type 1 Diabetes Companies- Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others

 

  • Type 1 Diabetes Pipeline Therapies- LABP 111, TTP 399, Teplizumab, Emricasan, VX 880, Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301, Dasiglucagon, SQZ TAC research program, Ent001, and others.

 

  • Type 1 Diabetes Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

 

Table of Content

1. Introduction

2. Executive Summary

3. Type 1 Diabetes: Overview

4. Type 1 Diabetes Pipeline Therapeutics

5. Type 1 Diabetes Therapeutic Assessment

6. Type 1 Diabetes- DelveInsight’s Analytical Perspective

7. Late Stage Products (Preregistration)

8. Teplizumab: Provention Bio

9. Mid Stage Products (Phase II)

10. TTP 399: Novo Nordisk

11. Early Stage Products (Phase I/II)

12. SBP 101: Takeda Oncology

13. Early Stage Products (Phase I)

14. Eflornithine oral: Panbela Therapeutics

15. Inactive Products

16. Type 1 Diabetes Key Companies

17. Type 1 Diabetes Key Products

18. Type 1 Diabetes- Unmet Needs

19. Type 1 Diabetes- Market Drivers and Barriers

20. Type 1 Diabetes- Future Perspectives and Conclusion

21. Type 1 Diabetes Analyst Views

22. Type 1 Diabetes Key Companies

23. Appendix

 

For further information on the Type 1 Diabetes Pipeline Therapeutics, reach out Type 1 Diabetes Market Drivers and Barriers

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/